The Claim

In adults with type 2 diabetes on metformin, a low dose of survodutide (0.9 mg weekly) reduces HbA1c to a similar extent as semaglutide (1.0 mg weekly) after 16 weeks, with adjusted mean reductions of -1.46% and -1.47% respectively.

Source: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
87score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Survodutide at 0.9 mg weekly lowers HbA1c by about 1.46% after 16 weeks in adults with type 2 diabetes on metformin, which is nearly identical to the 1.47% reduction from semaglutide at 1.0 mg weekly.

See the scientific wording

A low dose of survodutide (0.9 mg weekly) reduces HbA1c to a similar extent as the approved GLP-1 agonist semaglutide (1.0 mg weekly) after 16 weeks in adults with type 2 diabetes on metformin, with adjusted mean reductions of -1.46% vs -1.47%, respectively.

Why this might work

Survodutide acts like two natural hormones at once. One hormone tells the pancreas to release more insulin and stop releasing glucagon, which lowers blood sugar. The other hormone speeds up metabolism and burns fat. Together, these actions reduce blood sugar levels as effectively as the approved drug semaglutide.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

    The study found that a low dose of survodutide (0.9 mg per week) lowered blood sugar by about 1.46%, which is almost the same as the 1.47% reduction seen with the standard diabetes drug semaglutide, so the claim is correct.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.